231 related articles for article (PubMed ID: 31138496)
1. Caprazamycins: Biosynthesis and structure activity relationship studies.
Wiker F; Hauck N; Grond S; Gust B
Int J Med Microbiol; 2019 Jul; 309(5):319-324. PubMed ID: 31138496
[TBL] [Abstract][Full Text] [Related]
2. The biosynthesis of caprazamycins and related liponucleoside antibiotics: new insights.
Gust B; Eitel K; Tang X
Biol Chem; 2013 Feb; 394(2):251-9. PubMed ID: 23104838
[TBL] [Abstract][Full Text] [Related]
3. Caprazamycins: Promising lead structures acting on a novel antibacterial target MraY.
Patel B; Ryan P; Makwana V; Zunk M; Rudrawar S; Grant G
Eur J Med Chem; 2019 Jun; 171():462-474. PubMed ID: 30933853
[TBL] [Abstract][Full Text] [Related]
4. Mechanism of action of nucleoside antibacterial natural product antibiotics.
Bugg TDH; Kerr RV
J Antibiot (Tokyo); 2019 Dec; 72(12):865-876. PubMed ID: 31471595
[TBL] [Abstract][Full Text] [Related]
5. Structural insights into inhibition of lipid I production in bacterial cell wall synthesis.
Chung BC; Mashalidis EH; Tanino T; Kim M; Matsuda A; Hong J; Ichikawa S; Lee SY
Nature; 2016 May; 533(7604):557-560. PubMed ID: 27088606
[TBL] [Abstract][Full Text] [Related]
6. Antibacterial Nucleoside Natural Products Inhibiting Phospho-MurNAc-Pentapeptide Translocase; Chemistry and Structure-Activity Relationship.
Ichikawa S; Yamaguchi M; Matsuda A
Curr Med Chem; 2015; 22(34):3951-79. PubMed ID: 26282943
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and Medicinal Chemistry of Muraymycins, Nucleoside Antibiotics.
Katsuyama A; Ichikawa S
Chem Pharm Bull (Tokyo); 2018; 66(2):123-131. PubMed ID: 29386462
[TBL] [Abstract][Full Text] [Related]
8. Phospho-MurNAc-pentapeptide translocase (MraY) as a target for antibacterial agents and antibacterial proteins.
Bugg TD; Lloyd AJ; Roper DI
Infect Disord Drug Targets; 2006 Jun; 6(2):85-106. PubMed ID: 16789873
[TBL] [Abstract][Full Text] [Related]
9. Structures of Bacterial MraY and Human GPT Provide Insights into Rational Antibiotic Design.
Mashalidis EH; Lee SY
J Mol Biol; 2020 Aug; 432(18):4946-4963. PubMed ID: 32199982
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of phospho-MurNAc-pentapeptide translocase (MraY) by nucleoside natural product antibiotics, bacteriophage ϕX174 lysis protein E, and cationic antibacterial peptides.
Bugg TD; Rodolis MT; Mihalyi A; Jamshidi S
Bioorg Med Chem; 2016 Dec; 24(24):6340-6347. PubMed ID: 27021004
[TBL] [Abstract][Full Text] [Related]
11. Identification and manipulation of the caprazamycin gene cluster lead to new simplified liponucleoside antibiotics and give insights into the biosynthetic pathway.
Kaysser L; Lutsch L; Siebenberg S; Wemakor E; Kammerer B; Gust B
J Biol Chem; 2009 May; 284(22):14987-96. PubMed ID: 19351877
[TBL] [Abstract][Full Text] [Related]
12. Caprazamycins, novel lipo-nucleoside antibiotics, from Streptomyces sp. II. Structure elucidation of caprazamycins.
Igarashi M; Takahashi Y; Shitara T; Nakamura H; Naganawa H; Miyake T; Akamatsu Y
J Antibiot (Tokyo); 2005 May; 58(5):327-37. PubMed ID: 16060385
[TBL] [Abstract][Full Text] [Related]
13. Liposidomycin, the first reported nucleoside antibiotic inhibitor of peptidoglycan biosynthesis translocase I: The discovery of liposidomycin and related compounds with a perspective on their application to new antibiotics.
Kimura KI
J Antibiot (Tokyo); 2019 Dec; 72(12):877-889. PubMed ID: 31582803
[TBL] [Abstract][Full Text] [Related]
14. Self-Resistance during Muraymycin Biosynthesis: a Complementary Nucleotidyltransferase and Phosphotransferase with Identical Modification Sites and Distinct Temporal Order.
Cui Z; Wang XC; Liu X; Lemke A; Koppermann S; Ducho C; Rohr J; Thorson JS; Van Lanen SG
Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29735559
[TBL] [Abstract][Full Text] [Related]
15. Synthesis of the nucleoside moiety of liposidomycins: elucidation of the pharmacophore of this family of MraY inhibitors.
Dini C; Collette P; Drochon N; Guillot JC; Lemoine G; Mauvais P; Aszodi J
Bioorg Med Chem Lett; 2000 Aug; 10(16):1839-43. PubMed ID: 10969981
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of the first step in synthesis of the mycobacterial cell wall core, catalyzed by the GlcNAc-1-phosphate transferase WecA, by the novel caprazamycin derivative CPZEN-45.
Ishizaki Y; Hayashi C; Inoue K; Igarashi M; Takahashi Y; Pujari V; Crick DC; Brennan PJ; Nomoto A
J Biol Chem; 2013 Oct; 288(42):30309-30319. PubMed ID: 23986448
[TBL] [Abstract][Full Text] [Related]
17. Identification of novel inhibitors of phospho-MurNAc-pentapeptide translocase MraY from library screening: Isoquinoline alkaloid michellamine B and xanthene dye phloxine B.
Mihalyi A; Jamshidi S; Slikas J; Bugg TD
Bioorg Med Chem; 2014 Sep; 22(17):4566-71. PubMed ID: 25127465
[TBL] [Abstract][Full Text] [Related]
18. Muraymycin Nucleoside Antibiotics: Structure-Activity Relationship for Variations in the Nucleoside Unit.
Heib A; Niro G; Weck SC; Koppermann S; Ducho C
Molecules; 2019 Dec; 25(1):. PubMed ID: 31861655
[TBL] [Abstract][Full Text] [Related]
19. Crystal structure of MraY, an essential membrane enzyme for bacterial cell wall synthesis.
Chung BC; Zhao J; Gillespie RA; Kwon DY; Guan Z; Hong J; Zhou P; Lee SY
Science; 2013 Aug; 341(6149):1012-1016. PubMed ID: 23990562
[TBL] [Abstract][Full Text] [Related]
20. MraY Inhibitors as Novel Antibacterial Agents.
Dini C
Curr Top Med Chem; 2005; 5(13):1221-36. PubMed ID: 16305528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
